《復牌公告》泰凌醫藥(01011.HK)出售附屬泰凌醫藥國際 料錄收益3,410萬人幣 今早復牌
泰凌醫藥(01011.HK)公布,將Pfenex權益轉讓予附屬泰凌醫藥國際後,計劃以9億元人民幣(下同),將泰凌醫藥國際全部股權出售予北京康辰(603590.SH)旗下之康辰生物。出售交易後,泰凌醫藥將收購康辰生物40%股權,代價3.6億元,料就可能出售事項及Pfenex轉讓實現估計收益總額約3,410萬元。
Pfenex之權益為泰凌醫藥與美國生物科技公司Pfenex Inc.於2018年訂立的開發及獨家分銷權協議,公司表示,若繼續自行開發Pfenex,在可見將來屬巨大財務負擔,轉讓後則可與強大業務夥伴一同開發,令集團集中資源研發非典型抗精神病藥物「舒思」,是一種非典型抗精神病藥物。
公司於4月22日早上起短暫停止買賣,已向聯交所申請今日(28日)上午9時起復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.